Den europeiske union - norsk - EMA (European Medicines Agency)

astrazeneca ab - glycopyrronium, formoterol fumarate dihydrate - lungesykdom, kronisk obstruktiv - formoterol og glycopyrronium bromide - bevespi aerosphere er angitt som en vedlikehold bronkodilaterende behandling for å lindre symptomer hos voksne pasienter med kronisk obstruktiv lungesykdom (kols).

Den europeiske union - norsk - EMA (European Medicines Agency)

astrazeneca ab - andexanet alfa - narkotika-relaterte bivirkninger og uønskede reaksjoner - alle andre terapeutiske produkter - for voksne pasienter behandlet med en direkte faktor xa (anl) inhibitor (apixaban eller rivaroxaban) når reversering av antikoagulasjonsbehandling er nødvendig på grunn av livstruende eller ukontrollert blødning.

Den europeiske union - norsk - EMA (European Medicines Agency)

astrazeneca ab - metformin hydrochloride, saxagliptin, dapagliflozin - diabetes mellitus, type 2 - legemidler som brukes i diabetes - qtrilmet er indisert hos voksne i alderen 18 år og eldre med type 2 diabetes mellitus:for å bedre glykemisk kontroll når metformin med eller uten sulphonylurea (su) og enten saxagliptin eller dapagliflozin ikke gir tilstrekkelig glykemisk kontroll. når du allerede blir behandlet med metformin and saxagliptin og dapagliflozin.

Den europeiske union - norsk - EMA (European Medicines Agency)

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - lungesykdom, kronisk obstruktiv - legemidler for obstruktive sykdommer i luftveiene, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

Den europeiske union - norsk - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - leukemi, lymfocytisk, kronisk, b-celle - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Den europeiske union - norsk - EMA (European Medicines Agency)

astrazeneca ab - moxetumomab pasudotox - leukemi, hårete celler - antineoplastiske midler - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).

Den europeiske union - norsk - EMA (European Medicines Agency)

astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.

Den europeiske union - norsk - EMA (European Medicines Agency)

astrazeneca ab - anifrolumab - lupus erythematosus, systemisk - immunsuppressive - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.

Den europeiske union - norsk - EMA (European Medicines Agency)

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - lungesykdom, kronisk obstruktiv - legemidler for obstruktive sykdommer i luftveiene, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.

Den europeiske union - norsk - EMA (European Medicines Agency)

astrazeneca ab - tezepelumab - astma - legemidler for obstruktive sykdommer i luftveiene, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.